Staphylococcus haemolyticus (S. haemolyticus) (S. haemolyticus)

Staphylococcus haemolyticus is a Gram-positive, coagulase-negative bacterium that is a member of the normal human skin flora but functions as a significant opportunistic pathogen [1, 2]. It is one of the most frequently isolated coagulase-negative staphylococci in clinical settings, particularly associated with nosocomial infections such as prosthetic valve endocarditis, septicemia, and urinary tract infections [1, 4]. A defining characteristic of S. haemolyticus is its remarkable level of antimicrobial resistance; it frequently exhibits resistance to methicillin and is noted for its tendency to develop reduced susceptibility to glycopeptides like vancomycin [3]. The organism's ability to form biofilms on medical devices further complicates treatment and contributes to its persistence in hospital environments [4]. Therapeutic intervention typically requires the use of last-resort antibiotics such as linezolid or daptomycin, though resistance to these agents is also emerging [3]. Its genome is characterized by high plasticity, containing numerous insertion sequences that facilitate the acquisition and spread of resistance genes [3].

Other names

S. haemolyticusCoagulase-negative staphylococcus (CoNS)

Antibiotics targeting this organism function by inhibiting cell wall synthesis (glycopeptides), inhibiting protein synthesis (oxazolidinones, streptogramins), or disrupting the bacterial cell membrane (lipopeptides).